Recent FTC ruling discourages supplement research, Washington lawyer saysRecent FTC ruling discourages supplement research, Washington lawyer says
A proposed FTC consent decree finds that a study for BrainStrong was not sufficient to make congitive claims. Venable partner Todd Harrison says the high standard discourages research.
July 15, 2014
Todd Harrison says the cracks in DSHEA gaped a bit wider last month with the FTC’s proposed consent decree limiting claims by iHealth and Martek Biosciences for the BrainStrong Adult cognitive function supplement. The decree is a “shot through the heart” of the supplement industry, says Harrison, partner in Venable, a Washington D.C. law firm, and he worries whether the industry can mount the sort of response needed.
About the Author(s)
You May Also Like